Paxil-CR Articles
Generic Paxil launch hits GSK's shares
15 September 2003
New indications for three GlaxoSmithKline products
8 September 2003
CPMP reviewing safety of paroxetine-containing medicines
4 August 2003
Stock Commentary - Europe
28 July 2003
GSK 2nd-qtr earnings beat forecasts
28 July 2003
Stock Commentary - Europe
21 July 2003
Majors rush to roll out new drugs in Japan
14 July 2003
GSK's Wellbutrin XL on track for approval
7 July 2003
FDA reviewing GSK's Paxil safety
30 June 2003
GSK defends itself after FDA warning hits stock
30 June 2003
Stock Commentary - Europe
30 June 2003
Merck KGaA and GSK drop antidepressant
28 April 2003
GSK settles Paxil lawsuit with Par Pharma
28 April 2003
B-MS settles US FTC/states
17 March 2003
IVAX seeks approval for generic Flonase
17 March 2003
B-MS settles US FTC/states
17 March 2003
Stock Commentary - Europe
17 March 2003
Stock Commentary - Europe
10 March 2003
UK court blocks Seroxat generics
24 February 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
Key Paxil ruling comes early for GSK
20 January 2003
Stock Commentary - Europe
13 January 2003
B-MS to withdraw nefazodone in Europe
13 January 2003
Stock Commentary - Europe - 2 weeks to Dec 30
6 January 2003
Partial victory for GlaxoSmithKline in Paxil patent dispute
6 January 2003
10 most effective US DTC television ads
5 August 2002
Tokyo pharma stocks - week to June 24
1 July 2002
GSK launches Paxil CR antidepressant in USA
29 April 2002
GSK launches Paxil CR in USA
29 April 2002
Rise in US lawsuits for generic blocking
22 April 2002
SkyePharma achieve breakthrough
15 April 2002
SkyePharma climbs as GSK plans Paxil CR launch
1 April 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
US FTC probes Orange Book patent listings
14 January 2002
FDA appro for GSK's Paxil in post-traumatic stress disorder
7 January 2002
FDA appro for GSK's Paxil in post-traumatic stress disorder
17 December 2001
Par licenses first-filed Paxil capsule generic
28 November 2001
Endo takes on Paxil 40mg in USA
19 November 2001
Effects of generics on depression treatment market: study
9 November 2001
GSK troubled by Paxil lawsuit in USA
7 September 2001
Lawsuit against GSK says firm concealed Paxil
29 August 2001
Building market share in Japan: Datamonitor study
22 August 2001
FDA's tentative OK for generic Depakote
8 June 2001
Stock Commentary - New York
17 May 2001
Lilly's Prozac follow-up shows promise
9 May 2001
GSK's Paxil first SSRI for anxiety disorder
17 April 2001
SkyePharma's DepoCyt gains US clearance
5 March 2001
GSK restructuring its R&D to boost productivity
22 February 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Merck KGaA sets out plan to become number one in core businesses
20 February 2001
Merck KGaA CEO weighs up GSK antidepressant deal
16 February 2001
GSK fills product gap by licensing Merck KGaA antidepressant
15 February 2001
European psychotropics market forecasts
22 January 2001
FTC probe SB over Paxil suit
7 December 2000
W-A's Premarin is top US formulary drug
29 November 2000
SB introduces Paxil onto Japanese market
22 November 2000
Falling US sales for high-profile drugs
8 November 2000
SB sues Danish Medicines Agency over generic Paxil OK
2 November 2000
Strong earnings growth for Glaxo Wellcome and SmithKline Beecham
1 November 2000
Compare US Rx drug prices, consumers told
27 September 2000
Japan advisory panel to review SB Paxil dossier
3 August 2000
SB launches diabetes drug Avandia in UK
25 July 2000
SB's Paxil "improves hot flashes"
17 May 2000
SB files for Paxil in GAD
4 May 2000
Novo Nordisk sales increase 17%
21 February 2000
NeuroSearch signs $47m deal with GW
24 January 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
